Skip to main content

AbbVie vs Amgen: Founders, CEOs and History

AbbVie was founded in 2013 by Abbott Laboratories (spin-off origin) and is led by Robert A. Michael. Amgen was founded in 1980 by George B. Rathmann, William K. Bowes Jr. and is led by Robert A. Bradway.

Company facts

AbbVie

Founded
2013
Headquarters
North Chicago, Illinois
Current CEO
Robert A. Michael
Employees
57,000

Amgen

Founded
1980
Headquarters
Thousand Oaks, California
Current CEO
Robert A. Bradway
Employees
31,500

Founders

AbbVie

  • Abbott Laboratories (spin-off origin)

    Abbott Laboratories was AbbVie's corporate predecessor. AbbVie's official launch materials describe the company as formed in 2013 following separation from Abbott. Richard A.

AbbVie founders in full

Amgen

  • George B. Rathmann

    Amgen, originally incorporated as Applied Molecular Genetics, was founded in 1980 not by a single scientist, but by a calculated syndicate of venture capitalists and academics trying to commercialize the brand-new science of recombinant DNA.

  • William K. Bowes Jr.

    William K. Bowes Jr. Was the venture capital strategist whose vision catalyzed Amgen's formation.

Amgen founders in full

CEOs and their tenures

AbbVie

  1. Richard A. Gonzalez2013–2024

    Founding Chairman and Chief Executive Officer

    Served as AbbVie's chief executive officer from its formation in 2013 through June 2024 and as executive chairman through June 2025.

    Source
  2. Robert A. Michael2024–present

    Chairman and Chief Executive Officer

    Became chief executive officer on July 1, 2024 and chairman on July 1, 2025. He previously led finance, commercial operations, and corporate strategy roles at AbbVie.

    Source
AbbVie CEO history in full

Amgen

  1. George B. Rathmann1980–1988

    Chief Executive Officer

    George Rathmann, a physical chemist who had run research and development at Abbott Laboratories, was named Amgen's first chief executive in 1980 and worked from a small trailer so that laboratory space could go to scientists.

    Source
  2. Gordon M. Binder1988–2000

    Chief Executive Officer

    Gordon Binder joined Amgen as chief financial officer in 1982 and led its June 1983 initial public offering.

    Source
  3. Kevin W. Sharer2000–2012

    Chief Executive Officer

    Kevin Sharer joined Amgen in 1992 as president and chief operating officer and became chairman and chief executive in 2000.

    Source
  4. Robert A. Bradway2012–present

    Chairman and Chief Executive Officer

    Robert Bradway became chief executive on May 23, 2012, succeeding Kevin Sharer as the fourth CEO in Amgen's history, and added the chairmanship at the start of 2013.

    Source
Amgen CEO history in full

Timeline: AbbVie and Amgen side by side

  1. 1980Amgen

    Applied Molecular Genetics is incorporated

    Applied Molecular Genetics (AMGen) was incorporated on April 8, 1980 in Thousand Oaks, California, as the idea of venture capitalist William K. Bowes Jr. and a group of scientific collaborators.

  2. 1983Amgen

    Nasdaq listing and the erythropoietin clone

    Amgen completed its initial public offering on June 17, 1983, raising nearly US$40 million under chief financial officer Gordon Binder, and formally shortened its name to Amgen.

  3. 1984Amgen

    Kirin-Amgen joint venture formed

    Amgen and Kirin Brewery Company of Japan formed Kirin-Amgen in 1984 as a joint venture for the worldwide commercialization of erythropoietin.

  4. 1985Amgen

    G-CSF cloned, leading to Neupogen

    While Fu-Kuen Lin's team worked on erythropoietin, researcher Larry Souza and his group cloned and expressed human granulocyte colony-stimulating factor in 1985.

  5. 1989Amgen

    FDA approves Epogen

    The FDA approved Epogen (epoetin alfa) on June 1, 1989 for anemia in patients with chronic kidney failure on dialysis. It was the first commercial recombinant human erythropoietin. Epogen's U.S.

  6. 1991Amgen

    Neupogen approved, giving Amgen a second franchise

    The FDA approved Neupogen (filgrastim) in February 1991. By stimulating white blood cell production it reduced the risk of infection in cancer patients with chemotherapy-induced neutropenia.

  7. 1991Amgen

    Amgen wins the erythropoietin patent fight

    On March 6, 1991 the U.S. Court of Appeals for the Federal Circuit upheld the Kirin-Amgen erythropoietin patent and ruled against Genetics Institute in Amgen v. Chugai Pharmaceutical and Genetics Institute.

  8. 2001Amgen

    FDA approves Aranesp, the longer-acting EPO

    Aranesp (darbepoetin alfa), an erythropoietin analogue with modified glycosylation and a longer half-life, was approved in 2001. Less frequent dosing than Epogen improved convenience and gave Amgen a newer, higher-priced product to migrate patients toward.

  9. 2002Amgen

    US$16 billion Immunex acquisition brings Enbrel in-house

    Amgen completed its acquisition of Immunex Corporation on July 16, 2002, the largest biotechnology deal to that point at about US$16 billion in stock and cash.

  10. 2010Amgen

    Prolia and XGEVA create the bone health franchise

    The FDA approved Prolia (denosumab) for postmenopausal osteoporosis in June 2010 and XGEVA, the same molecule at a higher dose, for prevention of skeletal-related events in cancer patients in November 2010.

  11. 2013AbbVie

    AbbVie Launches as an Independent Company

    AbbVie launched after Abbott Laboratories separated its research-based pharmaceutical business and began NYSE trading under ABBV.

  12. 2015AbbVie

    Pharmacyclics Acquisition Completed

    AbbVie completed its acquisition of Pharmacyclics, adding Imbruvica and expanding its hematologic oncology business.

  13. 2019AbbVie

    Skyrizi Receives Initial U.S. Approval

    The FDA approved Skyrizi for adults with moderate to severe plaque psoriasis in April 2019.

  14. 2019AbbVie

    Rinvoq Receives Initial U.S. Approval

    The FDA approved Rinvoq for adults with moderate to severe rheumatoid arthritis in August 2019.

  15. 2019Amgen

    US$13.4 billion purchase of Otezla from Celgene

    Amgen agreed in August 2019 to buy worldwide rights to Otezla (apremilast) from Celgene for US$13.4 billion in cash, or about US$11.2 billion net of the present value of US$2.2 billion of anticipated future cash tax benefits, and closed on November 21, 2019.

  16. 2020AbbVie

    Allergan Acquisition Completed

    AbbVie completed the Allergan acquisition, adding neuroscience, eye care, and Allergan Aesthetics products including Botox and Juvederm.

  17. 2020Amgen

    Amgen joins the Dow Jones Industrial Average

    Amgen replaced Pfizer in the Dow Jones Industrial Average on August 31, 2020, becoming one of the thirty components in the index. Inclusion recognized the scale Amgen had reached and added passive demand from Dow-tracking funds.

  18. 2023AbbVie

    U.S. Humira Biosimilar Competition Begins

    Humira began facing U.S. biosimilar competition, and AbbVie reported a subsequent decline in Humira revenue.

  19. 2023Amgen

    US$27.8 billion Horizon Therapeutics acquisition closes

    Amgen completed the acquisition of Horizon Therapeutics plc on October 6, 2023 for US$116.50 per share in cash, an equity value of about US$27.8 billion, after settling FTC litigation with a behavioral consent decree.

  20. 2024AbbVie

    ImmunoGen Acquisition Completed

    AbbVie completed its acquisition of ImmunoGen, adding Elahere and antibody-drug conjugate programs.

  21. 2024AbbVie

    Robert A. Michael Becomes CEO

    Robert A. Michael succeeded Richard A. Gonzalez as chief executive officer effective July 1, 2024.

  22. 2024AbbVie

    Cerevel Therapeutics Acquisition Completed

    AbbVie completed its acquisition of Cerevel Therapeutics, adding clinical-stage neuroscience programs.

  23. 2024Amgen

    Imdelltra becomes the first T-cell engager for small cell lung cancer

    The FDA granted accelerated approval to tarlatamab, sold as Imdelltra, on May 16, 2024 for extensive stage small cell lung cancer that has progressed on or after platinum-based chemotherapy.

  24. 2025AbbVie

    Robert A. Michael Becomes Chairman

    Robert A. Michael added the chairman role effective July 1, 2025, when Richard A. Gonzalez retired from the board.

  25. 2025AbbVie

    FY2025 Revenue Reaches $61.160 Billion

    AbbVie reported FY2025 net revenue of $61.160 billion and net income of $4.226 billion.

  26. 2025Amgen

    VESALIUS-CV extends the Repatha case to primary prevention

    In November 2025 Amgen reported Phase 3 VESALIUS-CV results in more than 12,000 patients with atherosclerosis or diabetes but no prior heart attack or stroke.

  27. 2026AbbVie

    Q1 2026 Revenue Reaches $15.002 Billion

    AbbVie reported first-quarter 2026 net revenue of $15.002 billion, up 12.4 percent on a reported basis.

  28. 2026Amgen

    Medicare price setting reaches Enbrel and Otezla

    Enbrel's negotiated Medicare price under the Inflation Reduction Act took effect on January 1, 2026, after it was named in the first round of ten drugs selected for negotiation.

Acquisitions

AbbVie

  • ImmunoGen, Inc.2024$10.1B
  • Cerevel Therapeutics2024$8.7B
  • Allergan plc2020$63B
  • Pharmacyclics, Inc.2015$21B
All AbbVie acquisitions

Amgen

  • Horizon Therapeutics plc2023$27.8B
  • ChemoCentryx, Inc.2022$3.7B
  • Five Prime Therapeutics2021$1.9B
  • Celgene Otezla Business2019$13.4B
  • Onyx Pharmaceuticals, Inc.2013$10.4B
  • DeCODE Genetics2012$415M
All Amgen acquisitions

Questions about AbbVie vs Amgen

Who is the CEO of AbbVie Inc. and Amgen Inc.?

AbbVie Inc. is led by Robert A. Michael and Amgen Inc. is led by Robert A. Bradway. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.

When was AbbVie Inc. founded vs Amgen Inc.?

Amgen Inc. was founded in 1980 — 33 years before AbbVie Inc., which was founded in 2013. Amgen Inc.'s longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger AbbVie Inc..

How many employees does AbbVie Inc. have compared to Amgen Inc.?

AbbVie Inc. employs approximately 57,000 people, while Amgen Inc. employs approximately 31,500. AbbVie Inc. has the larger workforce at 57,000 employees, compared to Amgen Inc.'s 31,500. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).

Where are AbbVie Inc. and Amgen Inc. headquartered?

Both AbbVie Inc. and Amgen Inc. are headquartered in United States. Their local rules and tax obligations may still differ.

Who founded AbbVie Inc. and Amgen Inc.?

AbbVie Inc. was founded by Abbott Laboratories (spin-off origin). Amgen Inc. was founded by George B. Rathmann, William K. Bowes Jr..

Which company has a longer operating history — AbbVie Inc. or Amgen Inc.?

Amgen Inc. has been operating for approximately 46 years, making it the more established of the two companies. AbbVie Inc. has been in operation for around 13 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.

Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the AbbVie vs Amgen overview

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.